国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2015年
2期
126-129
,共4页
刘立峰%刘增儒%成志儒%王翠娴
劉立峰%劉增儒%成誌儒%王翠嫻
류립봉%류증유%성지유%왕취한
胃肿瘤%抗肿瘤联合化疗方案%生活质量%抗原,肿瘤相关,碳水化合物%健脾消癥方
胃腫瘤%抗腫瘤聯閤化療方案%生活質量%抗原,腫瘤相關,碳水化閤物%健脾消癥方
위종류%항종류연합화료방안%생활질량%항원,종류상관,탄수화합물%건비소징방
Stomach Neoplasms%Antineoplastic Combined Chemotherapy Protocols%Quality of Life%Antigens,Tumor-Associated,Carbohydrate%Jianpi-Xiaozheng recipe
目的：探讨自拟健脾消癥方联合化疗治疗晚期胃癌的临床疗效。方法收集2008年1月－2013年1月河北省新乐市社会保险职工医院肿瘤内科符合诊断标准的晚期胃癌患者124例，按照随机数字表法随机分为2组各62例，对照组采用SOX（奥沙利铂＋替吉奥）方案化疗，治疗组在对照组用药基础上，口服自拟中医健脾消癥方。采用实体瘤治疗反应标准评价治疗效果。分别采用欧洲肿瘤研究与治疗组织核心生活质量问卷调查量表（QLQ-C30）和Karnofsky行为状态量表（KPS）评价生活质量和身体状况。检测治疗前后血清肿瘤标记物糖类抗原199（CA199）、糖类抗原72-4（CA72-4）水平。结果治疗组缓解率（完全或部分缓解）显著高于对照组（62.9%比43.5%；χ2＝4.665，P＝0.031）。治疗组 QLQ-C30[(46.8±6.3)分比(42.2±5.9)分；t＝4.196，P＝0.001]和 KPS[(79.1±7.8)分比(72.0±7.5)分；t＝5.167，P＝0.000]评分较对照组显著增高。治疗组血清CA199[(61.7±16.5)U/ml比(113.3±21.4)U/ml；t＝15.036，P＝0.000]和 CA72-4[(27.9±9.6)U/ml 比(34.3±9.7)U/ml；t＝3.693，P＝0.001]较对照组显著降低。结论健脾消癥方联合化疗可提高晚期胃癌患者缓解率，降低血清肿瘤标记物水平，改善生活质量。
目的：探討自擬健脾消癥方聯閤化療治療晚期胃癌的臨床療效。方法收集2008年1月－2013年1月河北省新樂市社會保險職工醫院腫瘤內科符閤診斷標準的晚期胃癌患者124例，按照隨機數字錶法隨機分為2組各62例，對照組採用SOX（奧沙利鉑＋替吉奧）方案化療，治療組在對照組用藥基礎上，口服自擬中醫健脾消癥方。採用實體瘤治療反應標準評價治療效果。分彆採用歐洲腫瘤研究與治療組織覈心生活質量問捲調查量錶（QLQ-C30）和Karnofsky行為狀態量錶（KPS）評價生活質量和身體狀況。檢測治療前後血清腫瘤標記物糖類抗原199（CA199）、糖類抗原72-4（CA72-4）水平。結果治療組緩解率（完全或部分緩解）顯著高于對照組（62.9%比43.5%；χ2＝4.665，P＝0.031）。治療組 QLQ-C30[(46.8±6.3)分比(42.2±5.9)分；t＝4.196，P＝0.001]和 KPS[(79.1±7.8)分比(72.0±7.5)分；t＝5.167，P＝0.000]評分較對照組顯著增高。治療組血清CA199[(61.7±16.5)U/ml比(113.3±21.4)U/ml；t＝15.036，P＝0.000]和 CA72-4[(27.9±9.6)U/ml 比(34.3±9.7)U/ml；t＝3.693，P＝0.001]較對照組顯著降低。結論健脾消癥方聯閤化療可提高晚期胃癌患者緩解率，降低血清腫瘤標記物水平，改善生活質量。
목적：탐토자의건비소징방연합화료치료만기위암적림상료효。방법수집2008년1월－2013년1월하북성신악시사회보험직공의원종류내과부합진단표준적만기위암환자124례，안조수궤수자표법수궤분위2조각62례，대조조채용SOX（오사리박＋체길오）방안화료，치료조재대조조용약기출상，구복자의중의건비소징방。채용실체류치료반응표준평개치료효과。분별채용구주종류연구여치료조직핵심생활질량문권조사량표（QLQ-C30）화Karnofsky행위상태량표（KPS）평개생활질량화신체상황。검측치료전후혈청종류표기물당류항원199（CA199）、당류항원72-4（CA72-4）수평。결과치료조완해솔（완전혹부분완해）현저고우대조조（62.9%비43.5%；χ2＝4.665，P＝0.031）。치료조 QLQ-C30[(46.8±6.3)분비(42.2±5.9)분；t＝4.196，P＝0.001]화 KPS[(79.1±7.8)분비(72.0±7.5)분；t＝5.167，P＝0.000]평분교대조조현저증고。치료조혈청CA199[(61.7±16.5)U/ml비(113.3±21.4)U/ml；t＝15.036，P＝0.000]화 CA72-4[(27.9±9.6)U/ml 비(34.3±9.7)U/ml；t＝3.693，P＝0.001]교대조조현저강저。결론건비소징방연합화료가제고만기위암환자완해솔，강저혈청종류표기물수평，개선생활질량。
Objective To evaluate the efficacy of Jianpi-Xiaozheng recipe combined with chemotherapy in patients with late gastric cancer. Methods A total of 124 patients with late gastric cancer were randomly divided into a control group and a treatment group by random number table method, with 62 cases in each group. The patients in the control group received chemotherapy with S-1 and oxaliplatin (SOX), and those in the treatment group received Jianpi-Xiaozheng recipe combined with SOX chemotherapy. The treatment response was evaluated using the response evaluation criteria in solid tumors. The quality of life and physical status were evaluated with the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30) and Karnofsky Performance Status (KPS), respectivly. The serum levels of tumor biomarkers, carbohydrate antigen 199 (CA199) and carbohydrate antigen 72-4 (CA72-4) were detected before and after treatment. Results The response rate (complete or partial response) in the treatment group was significantly higher than that in the control group (62.9%vs. 43.5%;χ2=4.665, P=0.031). The scores of QLQ-C30 (46.8 ± 6.3 vs. 42.2 ± 5.9;t=4.196, P=0.001) and KPS (79.1 ± 7.8 vs. 72.0 ± 7.5;t=5.167, P=0.000) in the treatment group were significantly higher than those in the control group. The serum levels of CA199 (61.7 ± 16.5 U/ml vs. 113.3 ± 21.4 U/ml;t=15.036, P=0.000) and CA72-4 (27.9 ± 9.6 U/ml vs. 34.3 ± 9.7 U/ml;t=3.693, P=0.001) in the treatment group were significantly lower than those in the control group. Conclusions Jianpi-Xiaozheng recipe combined with chemotherapy can increase response rate, decrease the serum levels of tumor biomarkers, and improve the quality of life in patients with late gastric cancer.
